[go: up one dir, main page]

DK1278750T3 - Imidazopyrimidinderivater og triazolopyrimidinderivater - Google Patents

Imidazopyrimidinderivater og triazolopyrimidinderivater

Info

Publication number
DK1278750T3
DK1278750T3 DK01936242T DK01936242T DK1278750T3 DK 1278750 T3 DK1278750 T3 DK 1278750T3 DK 01936242 T DK01936242 T DK 01936242T DK 01936242 T DK01936242 T DK 01936242T DK 1278750 T3 DK1278750 T3 DK 1278750T3
Authority
DK
Denmark
Prior art keywords
derivatives
imidazopyrimidine
triazolopyrimidine
triazolopyrimidine derivatives
imidazopyrimidine derivatives
Prior art date
Application number
DK01936242T
Other languages
English (en)
Inventor
Ming Wang
Timothy B Lowinger
Takeshi Yura
Noriyuki Yamamoto
Arnel B Concepcion
Gyoonhee Han
Makiko Hiraoka
Hiroko Katsumata
Norihiro Kawamura
Toshio Kokubo
Hiroshi Komura
Yingfu Li
Muneto Mogi
Nagahiro Yoshida
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Application granted granted Critical
Publication of DK1278750T3 publication Critical patent/DK1278750T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK01936242T 2000-04-28 2001-04-17 Imidazopyrimidinderivater og triazolopyrimidinderivater DK1278750T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000128870A JP2001302667A (ja) 2000-04-28 2000-04-28 イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
PCT/EP2001/004357 WO2001083485A1 (en) 2000-04-28 2001-04-17 Imidazopyrimidine derivatives and triazolopyrimidine derivatives

Publications (1)

Publication Number Publication Date
DK1278750T3 true DK1278750T3 (da) 2004-11-22

Family

ID=18638240

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01936242T DK1278750T3 (da) 2000-04-28 2001-04-17 Imidazopyrimidinderivater og triazolopyrimidinderivater

Country Status (37)

Country Link
US (1) US6911443B2 (da)
EP (1) EP1278750B1 (da)
JP (2) JP2001302667A (da)
KR (1) KR20030009456A (da)
CN (1) CN1263756C (da)
AR (1) AR033367A1 (da)
AT (1) ATE272639T1 (da)
AU (1) AU783043B2 (da)
BG (1) BG107166A (da)
BR (1) BR0110404A (da)
CA (1) CA2407531A1 (da)
CZ (1) CZ20023551A3 (da)
DE (1) DE60104671T2 (da)
DK (1) DK1278750T3 (da)
DO (1) DOP2001000151A (da)
EE (1) EE200200606A (da)
ES (1) ES2225546T3 (da)
HR (1) HRP20020943A2 (da)
HU (1) HUP0300846A2 (da)
IL (1) IL151919A0 (da)
MA (1) MA25746A1 (da)
MX (1) MXPA02010579A (da)
MY (1) MY141578A (da)
NO (1) NO20025154L (da)
NZ (2) NZ526221A (da)
PE (1) PE20011287A1 (da)
PL (1) PL358106A1 (da)
PT (1) PT1278750E (da)
RU (1) RU2306313C2 (da)
SI (1) SI1278750T1 (da)
SK (1) SK15332002A3 (da)
SV (1) SV2001000416A (da)
TR (1) TR200402300T4 (da)
TW (1) TWI222974B (da)
UA (1) UA72615C2 (da)
WO (1) WO2001083485A1 (da)
ZA (1) ZA200207676B (da)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1385823T3 (da) 2001-04-09 2007-03-26 Novartis Vaccines & Diagnostic Guanidinoforbindelser som melanocortin-4-receptor- (MC4-R) -agonister
DE60303238T2 (de) 2003-04-25 2006-09-14 Actimis Pharmaceuticals, Inc., La Jolla Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
EP1674454A4 (en) * 2003-10-17 2006-12-27 Nippon Kayaku Kk SUBSTITUTED 2-AMINO-1,2,4-TRIAZOLO 1,5-A-PYRIMIDINE DERIVATIVE AND THE USE THEREOF
EP1694686A1 (en) 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
DE602005014849D1 (de) 2004-01-31 2009-07-23 Actimis Pharmaceuticals Inc Imidazoä1,2-cüpyrimidinylessigsäurederivate
MXPA06014637A (es) * 2004-06-25 2007-02-12 Amgen Inc Triazoles e indazoles condensados utiles en el tratamiento de enfermedades mediadas por citocinas y otras enfermedades.
JP2008510734A (ja) 2004-08-18 2008-04-10 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
CA2577782A1 (en) 2004-08-23 2006-03-02 Wyeth Pyrrolo-naphthyl acids as pai-1 inhibitors
KR20070055563A (ko) 2004-08-23 2007-05-30 와이어쓰 혈전증 및 심혈관 질병의 치료에 유용한 플라스미노겐활성화제 억제제 타입-1(pai-1)의 조절제로서의옥사졸로-나프틸 산
BRPI0514572A (pt) 2004-08-23 2008-06-17 Wyeth Corp ácidos de tiazolo-naftila
EP1812439B2 (en) * 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
AU2006219231B2 (en) 2005-02-28 2010-01-14 Japan Tobacco Inc. Novel aminopyridine compound with Syk inhibitory activity
US7442700B2 (en) * 2005-07-01 2008-10-28 Bristol-Myers Squibb Company Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
US20080004295A1 (en) * 2005-10-13 2008-01-03 Gore Paul M Novel compounds
CL2007002617A1 (es) * 2006-09-11 2008-05-16 Sanofi Aventis Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.
JP2010505962A (ja) 2006-10-09 2010-02-25 武田薬品工業株式会社 キナーゼ阻害剤
EP2223925A1 (en) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
GEP20125658B (en) * 2006-11-22 2012-10-10 Incyte Corp Imidazotriazines and imidazo pyrimidines as kinase inhibitors
KR20090103897A (ko) 2006-12-28 2009-10-01 다이쇼 세이야꾸 가부시끼가이샤 피라졸로피리미딘 화합물
DE102007012645A1 (de) 2007-03-16 2008-09-18 Bayer Healthcare Ag Substituierte Imidazo- und Triazolopyrimidine
CA2700525A1 (en) 2007-09-25 2009-04-02 Actimis Pharmaceuticals, Inc. 2-s-benzyl substituted pyrimidines as crth2 antagonists
PT2205569E (pt) 2007-09-25 2012-05-25 Actimis Pharmaceuticals Inc Alquiltiopirimidinas como antagonistas de crth2
DE102008023801A1 (de) 2008-05-15 2009-11-19 Bayer Schering Pharma Aktiengesellschaft Substituierte Imidazo- und Triazolopyrimidine, Imidazo- und Pyrazolopyrazine und Imidazotriazine
MX2011006094A (es) 2008-12-08 2011-11-29 Gilead Connecticut Inc Inhibidores de imidazopirazina syk.
KR101745732B1 (ko) 2008-12-08 2017-06-12 질레드 코네티컷 인코포레이티드 이미다조피라진 syk 억제제
EP2443123B1 (en) * 2009-06-15 2017-04-05 Rigel Pharmaceuticals, Inc. Small molecule inhibitors of spleen tyrosine kinase (syk)
KR101790255B1 (ko) 2009-12-23 2017-10-26 다케다 야쿠힌 고교 가부시키가이샤 Syk 억제제로서의 융합된 헤테로방향족 피롤리디논
BR112012022943A2 (pt) 2010-03-11 2018-06-05 Gilead Connecticut Inc inibidores de syk de imidazopiridnas
NZ603446A (en) * 2010-04-14 2014-05-30 Array Biopharma Inc 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of jak kinases
EP2706853B1 (en) 2011-05-10 2017-06-14 Merck Sharp & Dohme Corp. Aminopyrimidines as syk inhibitors
EP2706852B1 (en) 2011-05-10 2018-08-22 Merck Sharp & Dohme Corp. Bipyridylaminopyridines as syk inhibitors
JP2014513687A (ja) 2011-05-10 2014-06-05 メルク・シャープ・アンド・ドーム・コーポレーション Syk阻害薬としてのピリジルアミノピリジン
WO2012167423A1 (en) 2011-06-08 2012-12-13 Hutchison Medipharma Limited Substituted pyridopyrazines as novel syk inhibitors
EP2723739B1 (en) 2011-06-22 2016-08-24 Takeda Pharmaceutical Company Limited Substituted 6-aza-isoindolin-1-one derivatives
US9199975B2 (en) 2011-09-30 2015-12-01 Asana Biosciences, Llc Biaryl imidazole derivatives for regulating CYP17
US8987456B2 (en) 2011-10-05 2015-03-24 Merck Sharp & Dohme Corp. 3-pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
EP2763974B1 (en) 2011-10-05 2016-09-14 Merck Sharp & Dohme Corp. Phenyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
EP2763976B1 (en) 2011-10-05 2016-05-18 Merck Sharp & Dohme Corp. 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
CN103987713A (zh) * 2011-10-12 2014-08-13 阵列生物制药公司 5,7-取代的咪唑并[1,2-c]嘧啶
JP5868168B2 (ja) * 2011-12-28 2016-02-24 富士フイルム株式会社 新規なニコチンアミド誘導体またはその塩
WO2013192128A1 (en) 2012-06-20 2013-12-27 Merck Sharp & Dohme Corp. Imidazolyl analogs as syk inhibitors
EP2863914B1 (en) 2012-06-20 2018-10-03 Merck Sharp & Dohme Corp. Pyrazolyl derivatives as syk inhibitors
EP2863915B1 (en) 2012-06-22 2017-12-06 Merck Sharp & Dohme Corp. SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS
WO2013192098A1 (en) 2012-06-22 2013-12-27 Merck Sharp & Dohme Corp. SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS
WO2014031438A2 (en) 2012-08-20 2014-02-27 Merck Sharp & Dohme Corp. SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS
WO2014048065A1 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Triazolyl derivatives as syk inhibitors
US9624210B2 (en) 2012-12-12 2017-04-18 Merck Sharp & Dohme Corp. Amino-pyrimidine-containing spleen tyrosine kinase (Syk) inhibitors
EP2934525B1 (en) 2012-12-21 2019-05-08 Merck Sharp & Dohme Corp. Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors
US9745295B2 (en) 2013-04-26 2017-08-29 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
EP2988749B1 (en) 2013-04-26 2019-08-14 Merck Sharp & Dohme Corp. Thiazole-substituted aminopyrimidines as spleen tyrosine kinase inhibitors
PT3027171T (pt) 2013-07-30 2020-06-18 Gilead Connecticut Inc Formulação de inibidores da syk
MX2016001304A (es) 2013-07-30 2016-04-07 Gilead Connecticut Inc Polimorfo de inhibidores de syk.
SG11201603050TA (en) 2013-12-04 2016-05-30 Gilead Sciences Inc Methods for treating cancers
WO2015095445A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
US9670196B2 (en) 2013-12-20 2017-06-06 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as Spleen Tyrosine Kinase inhibitors
EP3082807B1 (en) 2013-12-20 2018-07-04 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
US9290505B2 (en) 2013-12-23 2016-03-22 Gilead Sciences, Inc. Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
TWI735853B (zh) 2013-12-23 2021-08-11 美商克洛諾斯生技有限公司 脾酪胺酸激酶抑制劑
WO2015138273A1 (en) 2014-03-13 2015-09-17 Merck Sharp & Dohme Corp. 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors
MX2016011784A (es) 2014-03-19 2016-12-02 Boehringer Ingelheim Int Nuevos heteroarilos y su uso como medicamentos.
MX2017000610A (es) 2014-07-14 2017-04-27 Gilead Sciences Inc Metodos combinados para tratar canceres.
HUE046920T2 (hu) 2015-09-11 2020-03-30 Boehringer Ingelheim Int Pirazolil-szubsztituált heteroarilszármazékok és gyógyszerként történõ alkalmazásuk
CN115028640A (zh) 2017-08-25 2022-09-09 吉利德科学公司 Syk抑制剂的多晶型物
MX2020004155A (es) 2017-10-19 2020-08-03 Bayer Animal Health Gmbh Uso de pirrolidonas heteroaromaticas fusionadas para el tratamiento y prevencion de enfermedades en animales.
US11673891B2 (en) 2017-11-14 2023-06-13 Dana-Farber Cancer Institute, Inc. Imidazopyrimidine compounds and uses thereof
JP7382316B2 (ja) * 2017-11-14 2023-11-16 ザ チルドレンズ メディカル センター コーポレーション ヒト免疫応答をモジュレートするためのイミダゾピリミジンの使用
EP3804722A4 (en) * 2018-06-06 2022-04-13 National University Corporation Hokkaido University TREATMENT AGENT AND PHARMACEUTICAL COMPOSITION AGAINST GLIOMA
WO2019235571A1 (ja) * 2018-06-06 2019-12-12 富士フイルム株式会社 血液がんの処置剤および医薬組成物
WO2019235572A1 (ja) * 2018-06-06 2019-12-12 富士フイルム株式会社 固形がんの処置剤および医薬組成物
CN117105933A (zh) 2018-10-31 2023-11-24 吉利德科学公司 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物
MX2021005047A (es) 2018-10-31 2021-09-08 Gilead Sciences Inc Compuestos de 6-azabenzimidazol sustituidos como inhibidores de hpk1.
KR20210131372A (ko) 2019-02-22 2021-11-02 크로노스 바이오, 인코포레이티드 Syk 억제제로서의 축합된 피라진의 고체 형태
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021173476A1 (en) * 2020-02-24 2021-09-02 The Trustees Of Columbia University In The City Of New York Compounds, pharmaceutical formulations, and methods for treatment of cancer
KR20230119134A (ko) * 2020-11-13 2023-08-16 바이오젠 엠에이 인코포레이티드 Btk 저해제로서의 피라졸로[1,5-a]피라진 유도체

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4483987A (en) 1983-06-20 1984-11-20 G. D. Searle & Co. 8-Substituted 7-phenyl-1,2,4-triazolo[2,3-c]pyrimidines-5-amines and amides
FR2549834B1 (fr) * 1983-07-25 1985-10-18 Sanofi Sa Derives de triazolo-pyrimidine, leur procede de preparation et leur application therapeutique en tant que tonicardiaques
EP1017682A4 (en) 1997-09-26 2000-11-08 Merck & Co Inc NEW ANGIOGENESIS INHIBITORS
JP4135318B2 (ja) * 1997-12-15 2008-08-20 アステラス製薬株式会社 新規なピリミジン−5−カルボキサミド誘導体
US6673564B2 (en) * 1999-10-18 2004-01-06 Millennium Pharmaceuticals, Inc. Methods for using 22045, a human cyclic nucleotide phosphodiesterase

Also Published As

Publication number Publication date
DOP2001000151A (es) 2002-05-15
JP2001302667A (ja) 2001-10-31
SK15332002A3 (sk) 2003-06-03
BG107166A (bg) 2003-06-30
ATE272639T1 (de) 2004-08-15
WO2001083485A1 (en) 2001-11-08
TWI222974B (en) 2004-11-01
PE20011287A1 (es) 2002-02-27
NO20025154D0 (no) 2002-10-25
TR200402300T4 (tr) 2004-12-21
EP1278750B1 (en) 2004-08-04
MY141578A (en) 2010-05-14
BR0110404A (pt) 2003-02-11
HRP20020943A2 (en) 2005-02-28
EE200200606A (et) 2004-04-15
KR20030009456A (ko) 2003-01-29
DE60104671T2 (de) 2005-12-29
EP1278750A1 (en) 2003-01-29
HUP0300846A2 (hu) 2003-08-28
ZA200207676B (en) 2003-09-25
NZ526221A (en) 2005-01-28
HK1058362A1 (en) 2004-05-14
SI1278750T1 (en) 2005-02-28
MXPA02010579A (es) 2003-05-14
RU2306313C2 (ru) 2007-09-20
JP2003535067A (ja) 2003-11-25
DE60104671D1 (de) 2004-09-09
MA25746A1 (fr) 2003-04-01
IL151919A0 (en) 2003-04-10
CN1439009A (zh) 2003-08-27
US20040054179A1 (en) 2004-03-18
CN1263756C (zh) 2006-07-12
ES2225546T3 (es) 2005-03-16
NZ522241A (en) 2004-04-30
NO20025154L (no) 2002-10-25
US6911443B2 (en) 2005-06-28
AU6220401A (en) 2001-11-12
CZ20023551A3 (cs) 2003-01-15
CA2407531A1 (en) 2001-10-25
SV2001000416A (es) 2001-07-03
PL358106A1 (en) 2004-08-09
AR033367A1 (es) 2003-12-17
UA72615C2 (en) 2005-03-15
AU783043B2 (en) 2005-09-22
PT1278750E (pt) 2004-11-30

Similar Documents

Publication Publication Date Title
DK1278750T3 (da) Imidazopyrimidinderivater og triazolopyrimidinderivater
NO991150D0 (no) Pyrazolopyrimidiner og pyrazolotriaziner
AR028622A1 (es) Derivados de tropano utiles en terapia
IS7283A (is) 3-ß-D-ríbófúranósýlþíasól[4,5-d]pýridímín kirnisleifar og notkun þeirra
DE60026297D1 (de) Pyrrolotriazin kinasehemmer
IS6385A (is) Ný notkun og nýjar N-asabísýkló-amíð afleiður
FI20000819L (fi) Menetelmä vastaanottimessa ja vastaanotin
EE200200452A (et) Puriinderivaadid
NO20041975L (no) Bicyklisk oksopyridin og oksopyrimidinderivater
DE60139930D1 (de) Desinfizieruns- und desodorierungsverfahren
DE60103537D1 (de) Purinderivate
DK1322597T3 (da) Fremgangsmåde og intermediære
DE60032898D1 (de) Arylthiazolidindion- und aryloxazolidinderivate
ATE512148T1 (de) Pyrazolo- und imidazopyrimidinderivate
DE50208341D1 (de) Triazolopyrimidine
ATE317386T1 (de) Dihydroindol- und tetrahydrochinolinderivate
DE50009171D1 (de) Co 2 - kompressor
NO20032821D0 (no) Sea-trosy og beslektede fremgangsmåter
DK1204566T3 (da) Sammenklappelig varebærer og råemne
DE60118970D1 (de) Indol- und dihydroindolderivate
GB2370001B (en) Educational aid
NO20031588D0 (no) Substituerte 3,4-dihydro-pyrimido(1,2-a)pyrimidiner og 3,4- dihydropyrazino(1,2-a)pyrimidiner
FR2815229B1 (fr) Cendrier portable
DE59905993D1 (de) Abschaltkupplung
DE50104434D1 (de) Lactam-substituierte pyrazolopyridinderivate